Show simple item record

Adding more content to screening: reactivation of FOXO as a therapeutic strategy.

dc.contributor.authorZanella, Fabian
dc.contributor.authorCarnero, Amancio
dc.date.accessioned2010-02-09T14:19:23Z
dc.date.available2010-02-09T14:19:23Z
dc.date.issued2009-10
dc.identifier.citationAdding more content to screening: reactivation of FOXO as a therapeutic strategy. 2009, 11 (10):651-8 Clin Transl Oncolen
dc.identifier.issn1699-3055
dc.identifier.pmid19828407
dc.identifier.doi10.1007/s12094-009-0420-0
dc.identifier.urihttp://hdl.handle.net/10541/91485
dc.description.abstractThe discovery of novel targets that can be pharmacologically exploited to lead to a better disease outcome has long been an aim of biomedical research. At present, the technology and robotisation available have pushed the search for novel molecules to a high-throughput screening (HTS) context, making it possible to screen several hundreds of compounds or genes in a single day. High-content screenings (HCS) have added a refined complexity to the screening processes, as the information drawn from an image- based assay is more complete than the monoparametric readouts obtained in classical HTS assays. Here, we review the development of HCS platforms to identify molecules influencing FOXO nuclear relocation and activation as pharmacological targets, their applicability and the future directions of the screening field.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAntineoplastic Agents
dc.subject.meshDrug Discovery
dc.subject.meshForkhead Transcription Factors
dc.subject.meshHigh-Throughput Screening Assays
dc.subject.meshHumans
dc.subject.meshNeoplasms
dc.titleAdding more content to screening: reactivation of FOXO as a therapeutic strategy.en
dc.typeArticleen
dc.contributor.departmentExperimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain.en
dc.identifier.journalClinical & Translational Oncologyen
html.description.abstractThe discovery of novel targets that can be pharmacologically exploited to lead to a better disease outcome has long been an aim of biomedical research. At present, the technology and robotisation available have pushed the search for novel molecules to a high-throughput screening (HTS) context, making it possible to screen several hundreds of compounds or genes in a single day. High-content screenings (HCS) have added a refined complexity to the screening processes, as the information drawn from an image- based assay is more complete than the monoparametric readouts obtained in classical HTS assays. Here, we review the development of HCS platforms to identify molecules influencing FOXO nuclear relocation and activation as pharmacological targets, their applicability and the future directions of the screening field.


This item appears in the following Collection(s)

Show simple item record